In a groundbreaking new study published in BMC Psychiatry, researchers have launched a large-scale randomized controlled trial to investigate the efficacy of cognitive behavioural therapy (CBT) designed specifically for young adults identified as being at high risk of developing bipolar disorder. This trial, known as Bipolar At Risk Trial II (BART II), represents a pivotal advance in early intervention strategies aimed at mitigating the progression of bipolar disorder, a complex and often debilitating mental health condition.
Bipolar disorder (BD) is characterized by extreme mood swings that can severely disrupt a person’s daily functioning and quality of life. Traditionally, diagnosis occurs only after mood episodes have manifested, sometimes years into the illness. However, recent advances in psychiatric research have paved the way for the identification of individuals in a prodromal or “at-risk” phase, commonly referred to as Bipolar At Risk (BAR). This emerging framework allows for the possibility of intervention before full-blown bipolar disorder develops, a concept the current study rigorously tests.
The trial is set in five National Health Service (NHS) centers across the United Kingdom and involves young adults who meet standardized BAR criteria. Participants are randomly assigned to one of two groups: the experimental group receiving tailored cognitive behavioural therapy combined with treatment as usual (CBT_BAR + TAU), and a control group receiving treatment as usual (TAU) only. The latter typically includes routine clinical support without specialized psychotherapeutic intervention targeting specific bipolar-related traits.
CBT_BAR is an adaptation of cognitive behavioural therapy, fine-tuned to address the extreme positive and negative appraisals individuals experience regarding their internal mood states. This modification is crucial, as the researchers hypothesize these appraisal patterns are central to mood instability and subsequent behavioural responses that can escalate into full episodes of bipolar disorder. By focusing on altering these key cognitive appraisals, the therapy aims to equip patients with better tools for mood regulation, potentially interrupting the trajectory toward bipolar disorder.
Participants are assessed at multiple time points: baseline, mid-treatment (17 weeks), post-treatment (27 weeks), and follow-up at one year (52 weeks). These assessments measure mood variability, functional outcomes, and quality of life indicators, among other clinical metrics. This longitudinal design allows the researchers not only to evaluate the immediate efficacy of CBT_BAR but also to determine its sustained impact over time, a critical consideration for any preventive intervention.
A unique aspect of the BART II trial is its embedded qualitative component, which seeks to evaluate the mechanisms through which CBT_BAR exerts its effects. This approach acknowledges that understanding how a treatment works is as important as whether it works, particularly in a complex clinical context where cognitive and emotional processes are deeply intertwined. Patient experiences, therapist feedback, and service delivery factors are analysed to assess feasibility and potential barriers to implementing CBT_BAR on a national scale.
The trial’s mechanistic hypothesis centers on a cognitive model of bipolar risk, proposing that the reduction of extreme internal state appraisals leads to behavioural changes that stabilize mood. This cascade effect underscores the therapy’s strategic focus on appraisal modification, distinguishing it from more generic CBT approaches. If supported, this would mark a significant paradigm shift in how psychological treatments for mood disorders are conceptualized and tailored.
Given the often chronic and recalcitrant nature of bipolar disorder, early intervention research like BART II is of immense clinical importance. Traditional pharmacological treatments, though effective to some extent, come with side effects and variable adherence, highlighting the need for robust psychological alternatives. CBT_BAR presents a non-pharmacological pathway that, if proven successful, could be integrated into existing NHS services to provide earlier, more targeted support.
Recruitment for the trial commenced in February 2023 and remains ongoing, with all protocols duly registered with the ISRCTN registry. This transparency and adherence to rigorous methodological standards enhance the credibility and reproducibility of the study, instilling confidence within the scientific community and among potential participants.
The implications of this research extend beyond bipolar disorder. By demonstrating that psychological therapies focused on cognitive appraisal can modify disease trajectories, it opens the door to preventive treatments for other complex psychiatric conditions where early cognitive and emotional markers play a critical role.
Moreover, the study’s focus on young adults addresses a demographic often marked by heightened vulnerability to mental health challenges. Emerging adulthood is a critical developmental window where interventions can yield maximal long-term benefits, potentially altering life course outcomes in a profound and positive way.
As findings from the BART II trial emerge over the coming years, the psychiatric field eagerly anticipates new insights into prevention—and possibly even remission—of bipolar disorder before the onset of debilitating episodes. This research epitomizes the shift toward personalized, mechanism-driven mental healthcare and exemplifies how scientific rigor and innovative therapy design can come together to address some of the most difficult challenges in psychiatry.
Subject of Research: Cognitive behavioural therapy versus treatment as usual in young adults at high risk of developing bipolar disorder.
Article Title: Cognitive behavioural therapy in comparison to treatment as usual in young adults at high risk of developing bipolar disorder (Bipolar At Risk): a randomised controlled trial to investigate the efficacy of a treatment approach targeted at key appraisal change: Bipolar At Risk Trial II (BART II).
Article References:
Parker, S., Pearson, L., Carney, R. et al. Cognitive behavioural therapy in comparison to treatment as usual in young adults at high risk of developing bipolar disorder (Bipolar At Risk): a randomised controlled trial to investigate the efficacy of a treatment approach targeted at key appraisal change: Bipolar At Risk Trial II (BART II). BMC Psychiatry 25, 649 (2025). https://doi.org/10.1186/s12888-025-06973-3
Image Credits: AI Generated
